A Seattle-based biotechnology company called Vedana Therapeutics has announced its public debut on Wednesday, securing $46 million in funding while assembling an experienced team of industry leaders specializing in advanced migraine treatment development.

The capital injection will enable the organization to progress its antibody-based therapies that target specific migraine-related signaling mechanisms, with the ultimate vision of creating treatments that patients can administer themselves through at-home injections.

The company’s ambition centers on establishing itself as the preeminent migraine treatment enterprise. Its assembled group of executives, board participants, and advisors bring substantial credentials in the field, having contributed to the creation of antibody treatments addressing two distinct protein categories: calcitonin gene-related peptides, commonly known as CGRP, and the more recently identified pituitary adenylate cyclase-activating
polypeptides, or PACAP.

According to co-founder and CEO Anurag Agarwal, the objective extends beyond symptom management. The company aims to develop medications capable of eliminating migraine episodes entirely, which requires addressing multiple biological mechanisms simultaneously rather than focusing on a single pathway, given the intricate and varied nature of the condition.

Despite CGRP-based medications marking a breakthrough as the initial targeted migraine therapies, approximately two-thirds of those suffering from migraines continue to experience symptoms. A migraine episode can produce a range of debilitating effects spanning several days, potentially including nausea, sensitivity to light, sleep disturbances, visual disturbances such as flashing lights or partial vision loss, headaches ranging from moderate to severe intensity, and subsequent fatigue and cognitive difficulties.

The primary drug development program at Vedana focuses on an advanced PACAP antibody formulation, while a secondary program targets both PACAP and CGRP simultaneously.

Chief Medical Officer Dr. Ernesto Aycardi emphasized the necessity of this comprehensive strategy, explaining that migraine pathology involves multiple neurotransmitters and proteins rather than a single causative agent. Additionally, the patient experience varies significantly, with individuals responding differently to various treatments and experiencing different triggers between episodes even within the same person.

The organization currently employs 14 people. Key leadership personnel include Agarwal, who previously served as an investor at Osage University Partners, an organization focused on commercializing academic research discoveries. Leon Garcia, serving as co-founder and chief scientific officer, brings experience from overseeing the discovery and development of both CGRP and PACAP antibodies during his tenure at Alder Biopharmaceuticals, a regional company that Lundbeck acquired seven years ago in a transaction valued at $1.95 billion.

Aycardi previously directed clinical development for the migraine medication AJOVY while at Teva. Dr. Rob Lenz, who chairs Vedana’s board of directors in an executive capacity, formerly headed global development at Amgen, where he guided the development of Aimovig, a competing migraine treatment.

Although numerous Seattle-area biotechnology firms are incorporating AI technologies into their medical therapy development processes, Vedana emphasizes its team’s extensive experience as a significant competitive advantage.

Agarwal noted that antibodies derived from living systems possess greater robustness than current large language models, having been refined through billions of years of evolutionary information, effectively leveraging that biological neural network. The company plans to incorporate AI technologies in subsequent phases of the drug development pipeline.

Major pharmaceutical corporations currently marketing approved CGRP antibody treatments include Amgen, Eli Lilly, Teva, and Lundbeck. Within the PACAP therapeutic space, Vedana competes against Lundbeck, Mentari Therapeutics, and Slate Medicines.

The Series A financing round received co-leadership from Westlake BioPartners and Canaan Partners, with additional investment from Dawn Biopharma and Alexandria Venture Investments.